News is out Victory Square Technologies Inc. (C-VST) - News Release
ORIGINAL: Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale & Use of Safetest Covid-19 Antibody Test for the Country of Brazil
2020-09-08 14:15 ET - News Release
VST Close 2020-09-04 C$ 0.59
- Victory Square Health received Brazilian ANIVSA approval for Safetest ELISA antibody test for distribution, sale, and usage throughout Brazil and export to Mercosur Countries (Argentina, Paraguay and Uruguay)
- Safetest Covid-19™ test enables the user to verify where they are infected, were infected or have never been infected with Covid-19
- Company ready for mass sale and distribution of ELISA Test in third largest Covid-19 infection rate Country to detect virus and help curb the spread
- This approval increases the company’s reach to the entire country of Brazil from prior accelerator approval from State of So Paulo release announced in late August
VANCOUVER, British Columbia, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. (“VS Health” or the "Company") – a portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) announced today that it was granted approval on Tuesday September 8, 2020 by The Brazilian Health Regulatory Agency (Anvisa) to commence marketing, sales and distribution for its Safetest ELISA Covid-19 assay for detecting the antibodies IgG and IgM against SARS-CoV-2, until 2030.